GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
葛兰素史克葛兰素史克(US:GSK) Businesswire·2026-03-13 23:44

公司产品动态 - GSK的呼吸道合胞病毒疫苗AREXVY在美国获得批准，将适用年龄范围扩大至18-49岁且风险增加的成年人群 [1] 行业监管进展 - 美国监管机构批准了RSV疫苗的年龄适应症扩展，为更广泛的成年人群提供预防选择 [1]

GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk - Reportify